Clinical Trials

12 enrolled 16 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05609942 2025-04-10

AZURE

9 enrolled

Leukemia, Mast-Cell, Mastocytosis, Systemic, Myelodysplastic-Myeloproliferative Diseases

NCT05476770 2024-12-06

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Phase 1 Recruiting

54 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Hodgkin Disease, Leukemia, Biphenotypic, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04275518 2024-10-15

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Phase 1 Recruiting

102 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05823480 2024-09-19

Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS

Phase 1 Withdrawn

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03814005 2024-09-05

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

17 enrolled 33 charts

Liver Diseases, Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Renal Insufficiency

NCT04243785 2024-03-20

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1 Recruiting

80 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04912063 2024-02-26

Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome

40 enrolled

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute

NCT05641259 2024-02-02

A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML

Phase 1 Unknown

198 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05107856 2024-01-31

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

21 enrolled

Lymphoma, Follicular, Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT02367456 2024-01-19

BRIGHT 1012

73 enrolled 31 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02543879 2023-11-21

Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies

94 enrolled

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02782468 2023-11-03

A Study of Pevonedistat in Adult East Asian Participants

23 enrolled 23 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05048498 2023-10-17

Pharmacokinetics, Tolerability and Safety of NEX-18a

2 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06008405 2023-09-06

Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy

Phase 1 Unknown

48 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05970822 2023-08-01

Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML

Phase 1 Unknown

32 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT03465540 2023-04-12

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

LymphoidMyeloidOther hematologic neoplasmPlasma cell

24 enrolled 21 charts

Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04022785 2022-10-31

PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

43 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT02319369 2021-10-11

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

74 enrolled 30 charts

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT02750995 2020-11-25

AZACTA

5 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02750254 2020-10-20

Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation

5 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00234000 2020-07-31

Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Classical hematologyMyeloidOther hematologic neoplasm

1 enrolled

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

BreastCNSDermatologicGenitourinaryGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcomaThoracic

89 enrolled

Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioblastoma, Hodgkin Disease, Kidney Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Skin Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Small Cell Lung Carcinoma

NCT01460498 2020-03-05

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

3 enrolled

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT02995655 2019-12-05

CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

20 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01519011 2019-11-12

Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine

34 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT00528983 2019-11-08

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia

133 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Juvenile

NCT00761722 2019-11-08

RACE

LymphoidMyeloidOther hematologic neoplasmPlasma cell

31 enrolled

Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02129101 2019-10-30

Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies

63 enrolled

Myelodysplastic Syndromes, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT03612739 2019-10-29

EPITHINK

Phase 1 Withdrawn

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00101179 2019-10-18

MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

63 enrolled